A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity

S. M. Offer, A. M. Lee, L. K. Mattison, C. Fossum, N. J. Wegner, Robert B Diasio

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene). In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers. The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min-1 mg-1; P = 0.00029). In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min-1 mg-1, respectively; P = 0.013).

Original languageEnglish (US)
Pages (from-to)158-166
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume94
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

Fluorouracil
African Americans
Enzymes
Dihydrouracil Dehydrogenase (NADP)
Volunteers
Colon
Breast
Neck
Head
Genes
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. / Offer, S. M.; Lee, A. M.; Mattison, L. K.; Fossum, C.; Wegner, N. J.; Diasio, Robert B.

In: Clinical Pharmacology and Therapeutics, Vol. 94, No. 1, 07.2013, p. 158-166.

Research output: Contribution to journalArticle

Offer, S. M. ; Lee, A. M. ; Mattison, L. K. ; Fossum, C. ; Wegner, N. J. ; Diasio, Robert B. / A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. In: Clinical Pharmacology and Therapeutics. 2013 ; Vol. 94, No. 1. pp. 158-166.
@article{a92bc1c605134ffbbaa6d44ca1d0fb77,
title = "A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity",
abstract = "5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene). In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers. The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46{\%} lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min-1 mg-1; P = 0.00029). In this study, 26{\%} of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27{\%} higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min-1 mg-1, respectively; P = 0.013).",
author = "Offer, {S. M.} and Lee, {A. M.} and Mattison, {L. K.} and C. Fossum and Wegner, {N. J.} and Diasio, {Robert B}",
year = "2013",
month = "7",
doi = "10.1038/clpt.2013.69",
language = "English (US)",
volume = "94",
pages = "158--166",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity

AU - Offer, S. M.

AU - Lee, A. M.

AU - Mattison, L. K.

AU - Fossum, C.

AU - Wegner, N. J.

AU - Diasio, Robert B

PY - 2013/7

Y1 - 2013/7

N2 - 5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene). In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers. The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min-1 mg-1; P = 0.00029). In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min-1 mg-1, respectively; P = 0.013).

AB - 5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene). In this study, the genetic associations between DPYD variations and circulating mononuclear-cell DPD enzyme activity were evaluated in 94 African-American and 81 European-American volunteers. The DPYD-Y186C variant was unique to individuals of African ancestry, and DPD activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol 5-FU min-1 mg-1; P = 0.00029). In this study, 26% of the African Americans with reduced DPD activity were carriers of Y186C. In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol 5-FU min-1 mg-1, respectively; P = 0.013).

UR - http://www.scopus.com/inward/record.url?scp=84879413456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879413456&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.69

DO - 10.1038/clpt.2013.69

M3 - Article

C2 - 23588312

AN - SCOPUS:84879413456

VL - 94

SP - 158

EP - 166

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -